-transparent.png){kind=logo}
CDF1 mice were implanted with 10(6) P388 leukemia cells. One day postimplantation, when interferon (IFN) therapy was begun, the tumor burden was ca. 4.8 X 10(6) cells. Therapy consisted of nine consecutive daily intraperitoneal (i.p.) injections of 10(6) units of Ehrlich ascites tumor cell IFN (specific activity 5 X 10(7) IU/mg). The median life span for control animals was 10.0 days versus 18.5 days for the treated animals. It was estimated that about 2 X 10(6) viable P388 cells were present on Day 9 when therapy was discontinued. There was no evidence of toxicity in animals receiving 10(6) units of IFN/day for nine consecutive days. In a separate experiment, control animals challenged as above had a median life span of 9.5 days of versus 15 days for animals receiving 10(6) units of IFN qd on Days 2-10. A third group of animals receiving a single injection of cis-DDP on Day 1 had a median survival of 18.5 days, while a fourth group receiving both cis-DDP on Day 1 and subsequent treatment with IFN survived 26 days. The results are discussed in terms of impact on tumor cell population.
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
January 1989,
Anticancer research,
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
March 1974,
Cancer chemotherapy reports. Part 2,
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
January 1993,
Anticancer research,
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
January 1984,
Oncology,
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
January 1996,
Zhongguo yao li xue bao = Acta pharmacologica Sinica,
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
December 1973,
National Cancer Institute monograph,
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
September 1994,
Cancer biochemistry biophysics,
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
January 1982,
Bulletin du cancer,
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
May 1985,
Cancer treatment reports,
S L Mowshowitz, and
S T Chin-Bow, and
G D Smith
August 1979,
Gan,
